BRPI0508488A - compostos terapêuticos - Google Patents

compostos terapêuticos

Info

Publication number
BRPI0508488A
BRPI0508488A BRPI0508488-1A BRPI0508488A BRPI0508488A BR PI0508488 A BRPI0508488 A BR PI0508488A BR PI0508488 A BRPI0508488 A BR PI0508488A BR PI0508488 A BRPI0508488 A BR PI0508488A
Authority
BR
Brazil
Prior art keywords
group
och
nme
phenylamino
cyclopentyl
Prior art date
Application number
BRPI0508488-1A
Other languages
English (en)
Inventor
Martyn Pritchard
Jacqueline Ouzman
Edward Savory
Giles Brown
Original Assignee
Cambridge Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0405012A external-priority patent/GB0405012D0/en
Priority claimed from GBGB0405009.2A external-priority patent/GB0405009D0/en
Priority claimed from PCT/GB2004/000902 external-priority patent/WO2004079329A2/en
Priority claimed from GB0412262A external-priority patent/GB0412262D0/en
Priority claimed from GB0412261A external-priority patent/GB0412261D0/en
Priority claimed from GB0413627A external-priority patent/GB0413627D0/en
Priority claimed from GB0419718A external-priority patent/GB0419718D0/en
Priority claimed from GB0420063A external-priority patent/GB0420063D0/en
Priority claimed from GB0420615A external-priority patent/GB0420615D0/en
Application filed by Cambridge Biotechnology Ltd filed Critical Cambridge Biotechnology Ltd
Publication of BRPI0508488A publication Critical patent/BRPI0508488A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)

Abstract

COMPOSTOS TERAPêUTICOS A invenção refere-se ao uso de compostos de fórmula geral (A) como medicamentos, em particular para o tratamento de dor ou inflamação; onde: (I) quando X = OH, R~ 2~ = NH~ 2~ , R~ 5~ = CH~ 2~OH, R~ 6~ = H , R~ 1~ é alcoxi C~ 5~-C~ 6~, OCH~ 2~-ciclopropil, O-(2,2,3,3-tetrafluorciclobutil), fenoxi, substituído, OCH~ 2~CH~ 2~OH, ou OCH~ 2~CHF~ 2~, (5-indanil) oxi, alquilamino C~ 1~, C~ 2~, C~ 5~, ou C~ 6~, (R) ou (S)-sec-butilamino, cicloalquilamino C~ 5~ ou C~ 6~, exonorbornanoamino, (N-metil, N-isoamilamino), fenilamino, fenilamino com substituintes ou metoxi ou fluor, um grupo sulfono C~ 2~, um grupo alquil C~ 2~, um grupo ciano, um grupo CONH~ 2~, ou 3,5-dimetilfenil; ou quando X = H, R~ 2~ = NH~ 2~, R~ 5~ = CH~ 2~OH , R~ 6~ = H, R~ 1~ é n-hexiloxi; ou (II) quando X = OH , R~ 1~ = H, R~ 5~ = CH~ 2~OH, R~ 6~ = H, R~ 2~ é NMe~ 2~, N-(2-isopentenil), piperazinil, (N-Me, N-benzil), (N-Me, N-CH~ 2~Ph(3-Br), (N-Me, N-CH~ 2~Ph (3-CF~ 3~)), ou (N-Me, N-(2-metoxietil)), ou OCH~ 2~-ciclopentil; ou (III) quando X = OH, R~ 5~ = CONHR~ 3~, R~ 6~ = H: R~ 1~ é H, R~ 3~ é um grupo isopropil, e R~ 2~ é ou NH~ 2~ ou um grupo metilamino (NHMe) ou um grupo isoamil (CH~ 2~CH~ 2~CHMe~ 2~); ou R~ 1~ é H, R~ 3~ é H, e R~ 2~ é NH~ 2~; ou R~ 1~ é OMe, R~ 3~ é Ph, e R~ 2~; ou R~ 1~ é NHCH~ 2~CH~ 2~CH~ 2~CH~ 2~CH~ 2~Me, R~ 3~ é CH~ 2~CH~ 2~CH~ 2~Me, e R~ 2~ é NH~ 2~; ou (IV) quando X = OH, R~ 1~ = H, R~ 2~ = NH~ 2~, = CH~ 2NHCOR~ 4~, R~ 6~ = H, R~ 4~ é n-propil ou NHCH~ 2~CH~ 3~; ou (V) quando X = OH, R~ 5~ = CH~ 2~OH, R~ 6~ = H: R~ 1~ é NH-ciclohexil quando R~ 2~é NMe~ 2~; ou R~ 1~ é OMe quando R~2~ é NH-benzil; ou (VI) quando X = OH, R~ 2~= NH~ 2~, R~ 5~ = CH~ 2~OH, R~ 6~ = Me, R~ 1~ é NH-ciclohexil ou NH-ciclopentil.
BRPI0508488-1A 2004-03-05 2005-03-04 compostos terapêuticos BRPI0508488A (pt)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB0405012A GB0405012D0 (en) 2004-03-05 2004-03-05 Therapeutic compounds
GBGB0405009.2A GB0405009D0 (en) 2004-03-05 2004-03-05 Analgesics
PCT/GB2004/000902 WO2004079329A2 (en) 2003-03-07 2004-03-05 Identification of therapeutic compounds
GB0412262A GB0412262D0 (en) 2004-06-02 2004-06-02 Use of compounds for the treatment of pain
GB0412261A GB0412261D0 (en) 2004-06-02 2004-06-02 Analgesics
GB0413627A GB0413627D0 (en) 2004-06-18 2004-06-18 Analgesics
GB0419718A GB0419718D0 (en) 2004-09-06 2004-09-06 Therapeutic compounds
GB0420063A GB0420063D0 (en) 2004-09-09 2004-09-09 Therapeutic compounds
GB0420615A GB0420615D0 (en) 2004-09-16 2004-09-16 Therapeutic compounds
PCT/GB2005/000800 WO2005084653A2 (en) 2004-03-05 2005-03-04 Adenosine receptor agonists

Publications (1)

Publication Number Publication Date
BRPI0508488A true BRPI0508488A (pt) 2007-07-31

Family

ID=34923594

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508488-1A BRPI0508488A (pt) 2004-03-05 2005-03-04 compostos terapêuticos

Country Status (12)

Country Link
US (1) US20080221060A1 (pt)
EP (1) EP1749016A2 (pt)
JP (1) JP2007526291A (pt)
KR (1) KR20070004792A (pt)
AU (1) AU2005218997B2 (pt)
BR (1) BRPI0508488A (pt)
CA (1) CA2557285A1 (pt)
EA (2) EA011099B1 (pt)
MX (1) MXPA06010075A (pt)
NO (1) NO20064365L (pt)
SG (1) SG144146A1 (pt)
WO (1) WO2005084653A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029264A2 (en) 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
US7396825B2 (en) * 2004-05-03 2008-07-08 University Of Virginia Patent Foundation Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
BRPI0517639A (pt) * 2004-11-08 2008-10-14 Can Fite Biopharma Ltd método para o tratamento de ressorção óssea acelerada, composição farmacêutica, e, uso de um agonista de a3ar
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
CN1947717B (zh) * 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
US20070183995A1 (en) * 2006-02-09 2007-08-09 Conopco, Inc., D/B/A Unilever Compounds useful as agonists of A2A adenosine receptors, cosmetic compositions with A2A agonists and a method for using the same
US8178509B2 (en) 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
JP5373599B2 (ja) * 2006-04-21 2013-12-18 ノバルティス アーゲー アデノシンａ２ａ受容体アゴニストとして使用するためのプリン誘導体
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
WO2008000743A2 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists
AU2007263728A1 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Adenosine derivatives for the treatment of pain
CN101479268B (zh) 2006-06-27 2012-08-08 Cbt发展有限公司 2-0’-甲基腺苷衍生物及其用作制备腺苷受体的激动剂或拮抗剂的应用
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
WO2009061516A1 (en) * 2007-11-08 2009-05-14 New York University School Of Medicine Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
CN101938904A (zh) * 2008-01-09 2011-01-05 PGx健康有限责任公司 用a2ar激动剂鞘内治疗神经性疼痛
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
SG177557A1 (en) * 2009-07-09 2012-02-28 Cbt Dev Ltd Combined preparation for use as a medicament
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
CA2783859A1 (en) * 2009-12-10 2011-06-16 Institute Of Materia Medica, Chinese Academy Of Medical Sciences N6-substituted adenosine derivatives and n6-substituted adenine derivatives and uses thereof
US20130109645A1 (en) * 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
CN103814030A (zh) * 2011-09-22 2014-05-21 辉瑞大药厂 吡咯并嘧啶及嘌呤衍生物
FR2981650B1 (fr) 2011-10-24 2013-12-27 Univ Paris Curie Analogues de nucleosides pour le traitement d'une infection virale et methode d'evaluation de la sensibilite audit traitement
WO2014028079A1 (en) * 2012-08-16 2014-02-20 Thomas Jefferson University Treatment of prostate cancer
US20150209379A1 (en) * 2012-08-16 2015-07-30 Thomas Jefferson University Treatment of prostate cancer and hematologic neoplasms
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
CA2930464A1 (en) * 2013-12-10 2015-06-18 Scinopharm Taiwan, Ltd. A process for the preparation of regadenoson
JP7136786B2 (ja) 2017-01-27 2022-09-13 アカデミア シニカ 痛みの予防および治療に使用するための鎮痛効果を有する化合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792155A (fr) * 1971-12-01 1973-05-30 Takeda Chemical Industries Ltd Nouveaux derives de l'adenosine et leur procede de production
JPS4861498A (pt) * 1971-12-01 1973-08-28
JPS5549594B2 (pt) * 1972-12-08 1980-12-12
DE2359536C2 (de) * 1972-12-08 1984-08-02 Takeda Chemical Industries, Ltd., Osaka 2,6-Diaminonebularinderivate
JPS5461194A (en) * 1977-10-21 1979-05-17 Takeda Chem Ind Ltd Preparation of n22substituted 2*66diaminonebularin
JPS5461195A (en) * 1977-10-21 1979-05-17 Takeda Chem Ind Ltd N2-substituted phenyl-2,6-diaminonebularin
US4705758A (en) * 1984-06-19 1987-11-10 Warner-Lambert Company Adenosine receptor assay and kit
US5013829A (en) * 1989-04-26 1991-05-07 University Of Iowa Research Foundation Stable congener of 2',3'-dideoxyadenosine
US5677290A (en) * 1990-05-10 1997-10-14 Fukunaga; Atsuo F. Therapeutic use of adenosine compounds as surgical anesthetics
US5679650A (en) * 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305149D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
GB0305150D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
US20090131651A1 (en) * 2003-12-05 2009-05-21 Giles Albert Brown Synthesis of 2-substituted adenosines
GB0328323D0 (en) * 2003-12-05 2004-01-07 Cambridge Biotechnology Ltd Synthesis of 2-substituted adenosines
GB0401292D0 (en) * 2004-01-21 2004-02-25 Cambridge Biotechnology Ltd Synthesis of spongosine

Also Published As

Publication number Publication date
EA200800538A1 (ru) 2008-06-30
US20080221060A1 (en) 2008-09-11
AU2005218997A1 (en) 2005-09-15
JP2007526291A (ja) 2007-09-13
EA011099B1 (ru) 2008-12-30
MXPA06010075A (es) 2007-04-10
KR20070004792A (ko) 2007-01-09
SG144146A1 (en) 2008-07-29
NO20064365L (no) 2006-11-22
EA014425B1 (ru) 2010-12-30
WO2005084653A3 (en) 2006-05-18
EA200601642A1 (ru) 2006-12-29
CA2557285A1 (en) 2005-09-15
AU2005218997B2 (en) 2012-05-10
EP1749016A2 (en) 2007-02-07
WO2005084653A2 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
BRPI0508488A (pt) compostos terapêuticos
ES440765A1 (es) Procedimiento para la obtencion de compuestos tetraciclicos.
ATE421321T1 (de) Methoden zur behandlung von angstzuständen
RU2003137565A (ru) Производные n-формилгидроксиламина в качестве ингибиторов пептидилдеформил азы (pdf)
DE59906365D1 (de) Benzamide mit tetrahydrofuranyloxy-substituenten als inhibitoren der phosphodiesterase 4
DE69423459T2 (de) Dihydrat des N-(4-Amino-6,7-dimethoxychinazol-2-yl)-N-methyl-N'-(tetrahydrofuroyl-2)-propylendiamin Hydrochlorids(=Alfuzosin Hydrochlorid Dihydrat) und ein Verfahren zur Herstellung
DE60239468D1 (de) Amphotere lipidverbindung und deren verwendung
TR200102585T2 (tr) Bifenil türevleri
PT1399144E (pt) Compostos carbamato para utilizacao na prevencao ou tratamento de disturbios de ansiedade
NZ332597A (en) Alkyloxyamino substituted fluoren-9-ones and their use as protein kinase c inhibitors
TW200724137A (en) Cancer treatment
BG103329A (en) Bis(acridinecarboxamide) and bis(phenazinecarboxamide) as antitumour agents
NO961537D0 (no) Salpetersyreestere fra derivater av 2-(2,6-dihalofenylamino)-fenylacetoksyeddiksyre, og deres fremstillingsprosedyrer
ATE266026T1 (de) Benzofurancarboxamide und deren therapeutische verwendung
EA199800446A1 (ru) Фунгицидные смеси
ATE340155T1 (de) Medizinische anwendungen von phenylalkanolen und derivaten davon
HUP0302212A2 (hu) Amidvegyület-alapú fungicid hatóanyag-keverék és alkalmazása
TH49162A (th) สารประกอบเททราไซคลิค อะซีพิโนอินโดล
TH62261A (th) อะซาไบไซคลิค คาร์บาเมต
TH78292B (th) สารประกอบชนิดใหม่
MY117739A (en) Chemical compounds
TH93841B (th) วิธีและสารผสมสำหรับการบำบัดการตอบสนองต่อการอักเสบ

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.